Malin has named Andrew von Eschenbach, M.D., as its chief medical adviser. The appointment puts the former FDA commissioner in a position to work with Immunocore, Poseida Therapeutics and the other cancer biotechs Malin has backed.
Von Eschenbach has worked with Malin since around the time Kelly Martin and other former Elan executives set up the fund and pulled off a €330 million ($390 million) IPO in 2015. But that earlier position on Malin’s scientific advisory board limited the extent to which von Eschenbach worked with the fund’s management team and portfolio companies.
Malin’s appointment of von Eschenbach as chief medical adviser will see the man who ran the FDA from 2006 to 2009 take a more active role in its activities, particularly those relating to its oncology and immuno-oncology investments.
Biotechs in these fields represent some of the biggest bets made by Malin so far. The Irish VC shop has invested more than €70 million in British immuno-oncology star Immunocore and a further €27 million in West Coast CAR-T and gene therapy startup Poseida.
With Immunocore’s lead candidate now in a pivotal trial and Poseida’s BCMA CAR-T in the clinic, a man with von Eschenbach’s background could prove useful.
“Now is a great time for me to join in a formal role as the portfolio continues to mature towards clinical and regulatory milestones,” von Eschenbach said in a statement.
Malin needs Immunocore and Poseida to plot a smoother course past these milestones than some of its other bets have managed. The fair value of most of Malin’s investments is equal or slightly above the amount it put into the companies. But the fund’s performance is marred by Novan and Serenus.
The combined fair value of Malin’s investments in the two companies stood at €16.2 million as of the end of June. Malin has invested €59.6 million in the two companies. The fund’s share price is down close to 20% over the past year.
Martin took over as CEO of Novan in June after the company was rocked by late-phase setbacks. At the end of last month, Martin stepped down as CEO of Malin to spend more time working with some of its portfolio companies, including Novan and Poseida.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
